Autoimmune disorder is a kind of common chronic disease, which is difficult to cure throughout life. Small chemical drugs such as glucocorticoids, immunosuppressors and non-steroidal anti-inflammatory drugs have been widely used for the treatment of autoimmune disorders. However, these small chemical drugs suffer from poor solubility, short circulating half-life and adverse side effects, which lead to poor compliance to patients and limit the widely clinical use. One of the most effective strategies to extend the circulating time is loading drugs into nanocarriers to form nanomedicines, which is of particular interest for cancer and viral diseases therapy but seldom applied in autoimmune disorder treatment. Furthermore, current carriers have many drawbacks such as poor biocompatibility, low stability and over-complicated design. In this study, we developed an easy but general drug delivery platform based on the new polyhydroxyalkanoate terpolymer-poly(3- hydroxybutyrate-co-3-hydroxyvalerate-co-3-hydroxyhexanoate) (PHBVHHx). We reported the first example of PHBVHHx nanoparticle loaded non-steroidal anti-inflammatory drug, ultimately being applied in systemic lupus erythematosus therapy. These nanoparticle are biodegradable, stable, and show improved pharmacokinetics, optimized biodistribution, low systemic toxicity and excellent in vivo therapeutic efficacy in a MLR/lpr murine model of systemic lupus erythematosus. This delivery system may provide a new and general platform for the development of nanomedicines with enhanced therapeutic efficacy and reduced side effects.<br/>

Polyhydroxyalkanoate-celecoxib nanoparticles for systemic lupus erythematosus therapy with enhanced efficacy and reduced side effects

2019 Spring National Meeting

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.